BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 33853673)

  • 1. Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs.
    Georgescu MM; Islam MZ; Li Y; Traylor J; Nanda A
    Acta Neuropathol Commun; 2021 Apr; 9(1):69. PubMed ID: 33853673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
    Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
    Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
    Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
    Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
    Dono A; El Achi H; Bundrant BE; Goli PS; Zhu P; Ozkizilkaya HI; Esquenazi Y; Ballester LY
    Cancer Biomark; 2023; 36(2):117-131. PubMed ID: 36530080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can adult
    Gilani A; Davies KD; Kleinschmidt-DeMasters BK
    Clin Neuropathol; 2021; 40(3):165-167. PubMed ID: 33769273
    [No Abstract]   [Full Text] [Related]  

  • 6. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
    Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
    Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.
    Gött H; Uhl E
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.
    Granberg KJ; Annala M; Lehtinen B; Kesseli J; Haapasalo J; Ruusuvuori P; Yli-Harja O; Visakorpi T; Haapasalo H; Nykter M; Zhang W
    Neuro Oncol; 2017 Sep; 19(9):1206-1216. PubMed ID: 28379477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.
    Ware KE; Marshall ME; Heasley LR; Marek L; Hinz TK; Hercule P; Helfrich BA; Doebele RC; Heasley LE
    PLoS One; 2010 Nov; 5(11):e14117. PubMed ID: 21152424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.
    Parker BC; Annala MJ; Cogdell DE; Granberg KJ; Sun Y; Ji P; Li X; Gumin J; Zheng H; Hu L; Yli-Harja O; Haapasalo H; Visakorpi T; Liu X; Liu CG; Sawaya R; Fuller GN; Chen K; Lang FF; Nykter M; Zhang W
    J Clin Invest; 2013 Feb; 123(2):855-65. PubMed ID: 23298836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
    Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
    J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR- gene family alterations in low-grade neuroepithelial tumors.
    Bale TA
    Acta Neuropathol Commun; 2020 Feb; 8(1):21. PubMed ID: 32085805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.
    Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
    Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.
    Métais A; Tauziède-Espariat A; Garcia J; Appay R; Uro-Coste E; Meyronet D; Maurage CA; Vandenbos F; Rigau V; Chiforeanu DC; Pallud J; Senova S; Saffroy R; Colin C; Edjlali M; Varlet P; Figarella-Branger D;
    Acta Neuropathol Commun; 2023 Jan; 11(1):14. PubMed ID: 36647073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.
    Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA
    Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
    Balasooriya ER; Wu Q; Ellis H; Zhen Y; Norden BL; Corcoran RB; Mohan A; Martin E; Franovic A; Tyhonas J; Lardy M; Grandinetti KB; Pelham R; Soroceanu L; Silveira VS; Bardeesy N
    Clin Cancer Res; 2024 May; 30(10):2181-2192. PubMed ID: 38437671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
    Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
    Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours.
    Parker BC; Engels M; Annala M; Zhang W
    J Pathol; 2014 Jan; 232(1):4-15. PubMed ID: 24588013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR3-TACC3 fusion in solid tumors: mini review.
    Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
    Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming fusions of FGFR and TACC genes in human glioblastoma.
    Singh D; Chan JM; Zoppoli P; Niola F; Sullivan R; Castano A; Liu EM; Reichel J; Porrati P; Pellegatta S; Qiu K; Gao Z; Ceccarelli M; Riccardi R; Brat DJ; Guha A; Aldape K; Golfinos JG; Zagzag D; Mikkelsen T; Finocchiaro G; Lasorella A; Rabadan R; Iavarone A
    Science; 2012 Sep; 337(6099):1231-5. PubMed ID: 22837387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.